Zacks Investment Research cut shares of Affimed (NASDAQ:AFMD) from a buy rating to a hold rating in a research note published on Friday.
According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “
Several other analysts also recently issued reports on the stock. Jefferies Financial Group raised shares of Affimed from a hold rating to a buy rating and upped their price objective for the stock from $1.80 to $4.00 in a report on Tuesday, August 28th. BidaskClub raised shares of Affimed from a strong sell rating to a sell rating in a report on Friday, August 31st. BMO Capital Markets decreased their price objective on shares of Affimed from $6.00 to $4.00 and set an outperform rating for the company in a report on Thursday, August 9th. ValuEngine raised shares of Affimed from a buy rating to a strong-buy rating in a report on Tuesday, August 28th. Finally, SunTrust Banks decreased their price objective on shares of Affimed to $5.00 and set a buy rating for the company in a report on Thursday, October 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Affimed currently has an average rating of Hold and an average target price of $4.81.
Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.05). The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.30 million. Affimed had a negative return on equity of 77.87% and a negative net margin of 2,124.72%. Equities research analysts forecast that Affimed will post -0.64 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new stake in Affimed in the 1st quarter valued at $4,731,000. FMR LLC bought a new stake in Affimed in the 3rd quarter valued at $5,552,000. EAM Global Investors LLC bought a new stake in Affimed in the 3rd quarter valued at $2,064,000. Dimensional Fund Advisors LP boosted its holdings in Affimed by 28.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 71,545 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Affimed by 38.8% in the 2nd quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 49,610 shares during the period. 40.62% of the stock is owned by hedge funds and other institutional investors.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Recommended Story: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.